The purpose of this study is to assess the safety and efficacy of Timolol Maleate treatment for different depth of infantile hemangioma based on B-ultrasonography. Based on the depth of hemangioma, patients will be proactively allocated to two groups. And then, all patients in both groups will receive topical timolol treatment in the same protocol and dosage.

Primary: Describe the efficacy of 0.5% topical timolol maleate drops in different depth of infantile hemangioma as assessed through IB-ultrasound.

Inclusion Criteria:

• Infants of 0 to 6 months of age
• Skin Infantile hemangiomas (IHs) in the proliferation stage without prior treatment
• IHs with a surface area of less than 1% of body surface area
• Skin type III/IV

Exclusion Criteria:

• Ulcerated IHs.
• Unsuitable for topical Timolol treatment due to anatomical location of lesion, eg.

periorbital and lip IHs.

• Patients with severe systemic or congenital disease which may affect the patient's safety in this study

Patients with infantile hemangiomas presented to the outpatient clinic of Shanghai Ninth People's Hospital would be considered for enrolment in the study. The diagnosis of proliferating infantile hemangioma is based on medical history and B-ultrasonography.